Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics announced a proposed offering of $400 million in convertible senior notes due 2032 to refinance its outstanding 2029 notes. The company intends to use a portion of the net proceeds to repurchase the 2.25% senior convertible notes due 2029, though the specific repurchase amount and price are still under negotiation. Remaining net proceeds will be used for general corporate purposes, including commercialization and R&D expenses, while J.P.
Key figures
- Deal Value Usd
- $400 million
- Offering Price
- to be determined at the time of the pricing of the offering
- Shares Offered
- $400 million aggregate principal amount
- Over allotment option
- $60 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.